

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Reporting Issuer

Cannvas MedTech Inc. (the “Company” or “Cannvas”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

Item 2: Date of Material Change

July 16, 2019.

Item 3: News Release

A news release was disseminated on July 16, 2019 and filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

The Company announced that it has closed the first tranche of a non-brokered private placement (the “**Private Placement**”) issuing a total of 5,007,500 units (“**Units**”) issued at a price of \$0.20 per Unit, raising gross proceeds of CDN\$1,001,500.

Item 5: Full Description of Material Change

The Company announced that it has closed the first tranche of a **Private Placement** of 5,007,500 Units issued at a price of \$0.20 per Unit, raising gross proceeds of CDN\$1,001,500. Each Unit consists of one common share and one transferable common share purchase warrant exercisable at \$0.30 per share for a period of two years.

Insiders of Cannvas subscribed for 275,000 Units, with Shawn Moniz, CEO and a director of the Company, subscribing for 125,000 Units through a company he controls; Steve Loutskou, COO and a director of the Company, subscribing for 125,000 Units through a company he controls; and Lindsay Hamelin, a director of the Company, subscribing for 25,000 Units through a company she controls. As a result, the Private Placement is a related party transaction (as defined under Multilateral Instrument 61-101 *Protection of Minority Security Holders in Special Transactions* (“**MI 61-101**”). The Company relied upon the “Issuer Not Listed on Specified Markets” and “Fair Market Value Not More Than \$2,500,000” exemptions from the formal valuation and minority shareholder approval requirements, respectively, under MI 61-101.

The Company intends to use the proceeds of the Private Placement for developing the technology platforms and general working capital.

Cannvas anticipates closing the second and final tranche of the financing in short order.

The Company paid finder’s fees of \$7,500 and 37,500 finder’s warrants to Echelon Wealth Partners Inc. All securities issued are subject to a four-month hold period.

About Cannvas MedTech Inc.

Cannvas is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

For further information, please contact:

CannvasMedTech.com

Contact: ir@cannvasmedtech.com

Item 9: Date of Report

July 16, 2019.